항정신병약물에 의한 대사부작용에 대한 이론과 대처방안

참고문헌 (138)

1. Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37, pp.1595~1607 (1988)
2. Laursen TM, "Excess early mortality in schizophrenia", Annu Rev Clin Psychol, 10, pp.425~448 (2014)
3. Ringen PA, "Increased mortality in schizophrenia due to cardiovascular disease-a non-systematic review of epidemiology, possible causes, and interventions", Front Psychiatry, 5, pp.137~ (2014)
4. Laursen TM, "Life expectancy among persons with schizophrenia or bipolar affective disorder", Schizophr Res, 131, pp.101~104 (2011)
5. Laursen TM, "Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries", PLoS One, 8, pp.e67133~ (2013)
6. Capasso RM, "Mortality in schizophrenia and schizoaffective disorder : an Olmsted County, Minnesota cohort : 1950-2005", Schizophr Res, 98, pp.287~294 (2008)
7. Foley DL, "Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis", Arch Gen Psychiatry, 68, pp.609~616 (2011)
8. Grundy SM, "Metabolic syndrome : connecting and reconciling cardiovascular and diabetes worlds", J Am Coll Cardiol, 47, pp.1093~1100 (2006)
9. Grundy SM, "Diagnosis and management of the metabolic syndrome : an American Heart Association", National Heart, Lung, and Blood Institute Scientific Statement, 2005, pp.112, 2735~2752
10. Banerji MA, "Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects", Am J Physiol, 273, pp.E425~E432 (1997)
11. Reaven G, "Syndrome X : 10 years after", Drugs, 58(Suppl 1), pp.19~20 (1999)
12. De Hert M, "Metabolic and cardiovascular adverse effects associated with antipsychotic drugs", Nat Rev Endocrinol, 8, pp.114~126 (2011)
13. Mitchell AJ, "Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis", Schizophr Bull, 39, pp.306~318 (2013)
14. Hasnain M, "Metabolic syndrome associated with schizophrenia and atypical antipsychotics", Curr Diab Rep, 10, pp.209~216 (2010)
15. De Hert M, "Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care", World Psychiatry, 10, pp.52~77 (2011)
16. Ford ES, "Prevalence of the metabolic syndrome among US adults : findings from the third National Health and Nutrition Examination Survey", JAMA, 287, pp.356~359 (2002)
17. Prevalence of metabolic syndrome in adult, "Ministry of Health & Welfare", Ministry of Health & Welfare, ~ (2017)
18. De Hert M, "Metabolic syndrome in people with schizophrenia : a review", World Psychiatry, 8, pp.15~22 (2009)
19. De Hert MA, "Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication", Schizophr Res, 83, pp.87~93 (2006)
20. McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia : baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE)schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2005)
21. Lee NY, "The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.1273~1278 (2011)
22. 이중선, "Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study", PSYCHIATRY INVESTIGATION, 14(1), pp.44~50 (2017), 대한신경정신의학회[DOI]
23. Vancampfort D, "A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls", World Psychiatry, 12, pp.240~250 (2013)
24. De Hert M, "Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness : a cross-sectional study", Clin Pract Epidemiol Ment Health, 2, pp.14~ (2006)
25. Meyer JM, "The metabolic syndrome and schizophrenia", Acta Psychiatr Scand, 119, pp.4~14 (2009)
26. Bhargava A, "A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study", Popul Health Metr, 1, pp.3~ (2003)
27. Arango C, "A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome : findings from the CLAMORS study", Schizophr Res, 104, pp.1~12 (2008)
28. Brown S, "Excess mortality of schizophrenia. A meta-analysis", Br J Psychiatry, 171, pp.502~508 (1997)
29. Brown S, "Causes of the excess mortality of schizophrenia", Br J Psychiatry, 177, pp.212~217 (2000)
30. Osby U, "Mortality and causes of death in schizophrenia in Stockholm county, Sweden", Schizophr Res, 45, pp.21~28 (2000)
31. Isomaa B, "Cardiovascular morbidity and mortality associated with the metabolic syndrome", Diabetes Care, 24, pp.683~689 (2001)
32. Lyketsos CG, "Medical comorbidity in psychiatric inpatients : relation to clinical outcomes and hospital length of stay", Psychosomatics, 43, pp.24~30 (2002)
33. Dixon L, "The association of medical comorbidity in schizophrenia with poor physical and mental health", J Nerv Ment Dis, 187, pp.496~502 (1999)
34. Robinson DG, "Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder", Schizophr Res, 57, pp.209~219 (2002)
35. Weiden PJ, "Obesity as a risk factor for antipsychotic noncompliance", Schizophr Res, 66, pp.51~57 (2004)
36. Saha S, "A systematic review of mortality in schizophrenia : is the differential mortality gap worsening over time", Arch Gen Psychiatry, 64, pp.1123~1131 (2007)
37. Hennekens CH, "Schizophrenia and increased risks of cardiovascular disease", Am Heart J, 150, pp.1115~1121 (2005)
38. Druss BG, "Understanding excess mortality in persons with mental illness : 17-year follow up of a nationally representative US survey", Med Care, 49, pp.599~604 (2011)
39. Hayes JF, "Mortality gap for people with bipolar disorder and schizophrenia : UK-based cohort study 2000-2014", Br J Psychiatry, 211, pp.175~181 (2017)
40. Morrato EH, "Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes", Diabetes Care, 32, pp.1037~1042 (2009)
41. Mackin P, "A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients", BMC Psychiatry, 7, pp.28~ (2007)
42. Nasrallah HA, "Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia : data from the CATIE schizophrenia trial sample at baseline", Schizophr Res, 86, pp.15~22 (2006)
43. Newcomer JW, "Second-generation(atypical)antipsychotics and metabolic effects : a comprehensive literature review", CNS Drugs, 19(Suppl 1), pp.1~93 (2005)
44. Cradock-O’Leary J, "Use of general medical services by VA patients with psychiatric disorders", Psychiatr Serv, 53, pp.874~878 (2002)
45. Druss BG, "Quality of medical care and excess mortality in older patients with mental disorders", Arch Gen Psychiatry, 58, pp.565~572 (2001)
46. Kim SF, "From the cover : antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase", Proc Natl Acad Sci U S A, 104, pp.3456~3459 (2007)
47. Kroeze WK, "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs", Neuropsychopharmacology, 28, pp.519~526 (2003)
48. Solmi M, "Safety, tolerability, and risks associated with first-and second-generation antipsychotics : a state-of-the-art clinical review", Ther Clin Risk Manag, 13, pp.757~777 (2017)
49. Correll CU, "Antipsychotic drugs and obesity", Trends Mol Med, 17, pp.97~107 (2011)
50. Silvestre JS, "Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes", Methods Find Exp Clin Pharmacol, 27, pp.289~304 (2005)
51. Scaini G, "Second generation antipsychotic-induced mitochondrial alterations : implications for increased risk of metabolic syndrome in patients with schizophrenia", Eur Neuropsychopharmacol, 28, pp.369~380 (2018)
52. Abdel-Wahab BA, "Clozapine-induced cardiotoxicity : role of oxidative stress, tumour necrosis factor alpha and NF-κβ", Cardiovasc Toxicol, 15, pp.355~365 (2015)
53. Stubbs B, "Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis", Psychoneuroendocrinology, 63, pp.144~154 (2016)
54. Goetz RL, "Meta-analysis of ghrelin alterations in schizophrenia:effects of olanzapine", Schizophr Res (2018)
55. Yevtushenko OO, "Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia", Br J Psychiatry, 192, pp.424~428 (2008)
56. Suetani RJ, "Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis", Psychopharmacology (Berl), 234, pp.2989~3008 (2017)
57. Bai YM, "Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics", Schizophr Res, 125, pp.179~186 (2011)
58. Peet M, "Diet, diabetes and schizophrenia : review and hypothesis", Br J Psychiatry Suppl, 47, pp.S102~S105 (2004)
59. De Leon J, "A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors", Schizophr Res, 76, pp.135~157 (2005)
60. Tsuruga K, "Dietary patterns and schizophrenia : a comparison with healthy controls", Neuropsychiatr Dis Treat, 11, pp.1115~1120 (2015)
61. Hasnain M, "Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications", Prim Care Diabetes, 3, pp.5~15 (2009)
62. Baker RA, "Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database : a systematic Bayesian signal detection analysis", Psychopharmacol Bull, 42, pp.11~31 (2009)
63. Duncan EJ, "Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a veterans affairs population", Int Clin Psychopharmacol, 24, pp.204~213 (2009)
64. Sicras-Mainar A, "Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia", Neuropsychiatr Dis Treat, 11, pp.51~57 (2015)
65. Hammerman A, "Antipsychotics and diabetes : an age-related association", Ann Pharmacother, 42, pp.1316~1322 (2008)
66. Correll CU, "Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents", J Clin Psychiatry, 69(Suppl 4), pp.26~36 (2008)
67. Kumra S, "Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia", Schizophr Bull, 34, pp.60~71 (2008)
68. Holt RI, "Obesity, serious mental illness and antipsychotic drugs", Diabetes Obes Metab, 11, pp.665~679 (2009)
69. Coccurello R, "Potential mechanisms of atypical antipsychotic-induced metabolic derangement : clues for understanding obesity and novel drug design", Pharmacol Ther, 127, pp.210~251 (2010)
70. Fernandez-Egea E, "Metabolic profile of antipsychotic-naive individuals with non-affective psychosis", Br J Psychiatry, 194, pp.434~438 (2009)
71. Ryan MC, "The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia", Life Sci, 74, pp.1999~2008 (2004)
72. Sengupta S, "Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls", Schizophr Res, 102, pp.329~336 (2008)
73. Enez Darcin A, "Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings", Schizophr Res, 166, pp.201~206 (2015)
74. Ryan MC, "Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia", Am J Psychiatry, 160, pp.284~289 (2003)
75. Nielsen J, "Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients", Neuropsychopharmacology, 35, pp.1997~2004 (2010)
76. Cohen D, "Endogenic and iatrogenic diabetes mellitus in drug-naïve schizophrenia : the role of olanzapine and its place in the psychopharmacological treatment algorithm", Neuropsychopharmacology, 36, pp.2368~2369 (2011)
77. Cohn TA, "Insulin resistance and adiponectin levels in drug-free patients with schizophrenia : a preliminary report", Can J Psychiatry, 51, pp.382~386 (2006)
78. Spelman LM, "Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia", Diabet Med, 24, pp.481~485 (2007)
79. Kirkpatrick B, "Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits", Schizophr Bull, 38, pp.280~284 (2012)
80. Thakore JH, "Metabolic syndrome and schizophrenia", Br J Psychiatry, 186, pp.455~456 (2005)
81. Tschoner A, "Metabolic side effects of antipsychotic medication", Int J Clin Pract, 61, pp.1356~1370 (2007)
82. Graham KA, "Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis", Am J Psychiatry, 162, pp.118~123 (2005)
83. Wu RR, "Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia", Psychopharmacology(Berl), 186, pp.572~578 (2006)
84. Lieberman JA, "Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol", Am J Psychiatry, 160, pp.1396~1404 (2003)
85. Sengupta SM, "Weight gain and lipid metabolic abnormalities induced by olanzapine in firstepisode, drug-naïve patients with psychotic disorders", Schizophr Res, 80, pp.131~133 (2005)
86. Kohen D, "Diabetes mellitus and schizophrenia : historical perspective", Br J Psychiatry Suppl, 47, pp.S64~S66 (2004)[DOI]
87. Scheen AJ, "Abnormal glucose metabolism in patients treated with antipsychotics", Diabetes Metab, 33, pp.169~175 (2007)
88. Hirsch L, "Secondgeneration antipsychotics and metabolic side effects : a systematic review of population-based studies", Drug Saf, 40, pp.771~781 (2017)
89. Newcomer JW, "The metabolic effects of antipsychotic medications", Can J Psychiatry, 51, pp.480~491 (2006)
90. Ono S, "High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia : post-hoc analysis of a Japanese nationwide survey", BMC Psychiatry, 18, pp.180~ (2018)
91. Smith M, "First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis", Br J Psychiatry, 192, pp.406~411 (2008)
92. Liao CH, "Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia : a population-based study", Schizophr Res, 126, pp.110~116 (2011)
93. Kessing LV, "Treatment with antipsychotics and the risk of diabetes in clinical practice", Br J Psychiatry, 197, pp.266~271 (2010)
94. Luckhoff H, "Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months", Schizophr Res (2018)
95. Sharma E, "Association between antipsychotic-induced metabolic side-effects and clinical improve ment: a review on the evidence for “metabolic threshold.”", Asian J Psychiatr, 8, pp.12~21 (2014)
96. Kemp DE, "Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia", J Child Adolesc Psychopharmacol, 23, pp.522~530 (2013)
97. Grover S, "Metabolic disturbances, side effect profile and effectiveness of clozapine in adolescents", Indian J Psychol Med, 38, pp.224~233 (2016)
98. Raben AT, "The complex relationship between antipsychotic-induced weight gain and therapeutic benefits : a systematic review and implications for treatment", Front Neurosci, 11, pp.741~ (2017)
99. De Hert M, "Typical and atypical antipsychotics differentially affect longterm incidence rates of the metabolic syndrome in first-episode patients with schizophrenia : a retrospective chart review", Schizophr Res, 101, pp.295~303 (2008)
100. De Hert M, "Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association(EPA), supported by the European Association for the Study of Diabetes(EASD)and the European Society of Cardiology(ESC)", Eur Psychiatry, 24, pp.412~424 (2009)
101. Straker D, "Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications", Am J Psychiatry, 162, pp.1217~1221 (2005)
102. Tirupati S, "Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders", Australas Psychiatry, 15, pp.470~473 (2007)
103. American Diabetes Association, "Consensus development conference on antipsychotic drugs and obesity and diabetes", Diabetes Care, 27, pp.596~601 (2004)
104. Cooper SJ, "BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment", J Psychopharmacol, 30, pp.717~748 (2016)
105. Gabriele JM, "Efficacy of behavioural interventions in managing atypical antipsychotic weight gain", Obes Rev, 10, pp.442~455 (2009)
106. Alvarez-Jiménez M, "Non-pharmacological management of antipsychoticinduced weight gain : systematic review and meta-analysis of randomised controlled trials", Br J Psychiatry, 193, pp.101~107 (2008)
107. Sugawara N, "Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan : a randomized controlled trial", J Psychiatr Res, 97, pp.77~83 (2018)
108. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
109. Lakka TA, "Physical activity in prevention and treatment of the metabolic syndrome", Appl Physiol Nutr Metab, 32, pp.76~88 (2007)
110. Gurusamy J, "Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia : a systematic review", Asian J Psychiatr, 36, pp.73~85 (2018)
111. Hermes E, "The association between weight change and symptom reduction in the CATIE schizophrenia trial", Schizophr Res, 128, pp.166~170 (2011)
112. Stroup TS, "Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic", Am J Psychiatry, 163, pp.611~622 (2006)
113. Weiden PJ, "Longterm changes in weight and plasma lipids during maintenance treatment with ziprasidone", Neuropsychopharmacology, 33, pp.985~994 (2008)
114. Zheng W, "Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment : meta-analysis of randomized placebo-controlled trials", J Clin Psychopharmacol, 35, pp.499~509 (2015)
115. Ellul P, "Metformin for weight gain associated with second-generation antipsychotics in children and adolescents : a systematic review and meta-analysis", CNS Drugs, 32, pp.1103~1112 (2018)
116. Siskind DJ, "Metformin for clozapine associated obesity : a systematic review and metaanalysis", PLoS One, 11, pp.e0156208~ (2016)
117. Fabrazzo M, "Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time-and dose-dependent manner", J Clin Psychopharmacol, 20, pp.708~710 (2000)
118. Lu ML, "Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia : a 12-week, randomized, double-blind, placebo-controlled study", Schizophr Res, 193, pp.126~133 (2018)
119. Lu ML, "Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances", J Clin Psychiatry, 65, pp.766~771 (2004)
120. Porfirio MC, "Can melatonin prevent or improve metabolic side effects during antipsychotic treatments", Neuropsychiatr Dis Treat, 13, pp.2167~2174 (2017)
121. Agahi M, "Effect of melatonin in reducing second-generation antipsychotic metabolic effects : a double blind controlled clinical trial", Diabetes Metab Syndr, 12, pp.9~15 (2018)
122. Romo-Nava F, "Melatonin attenuates antipsychotic metabolic effects : an eight-week randomized, doubleblind, parallel-group, placebo-controlled clinical trial", Bipolar Disord, 16, pp.410~421 (2014)
123. Koziróg M, "Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome", J Pineal Res, 50, pp.261~266 (2011)
124. Lee SY, "Cutoff points of waist circumference for defining abdominal obesity in the Korean population", Korean J Obes, 15, pp.1~9 (2006)
125. Sugawara N, "Prevalence of metabolic syndrome among patients with schizophrenia in Japan", Schizophr Res, 123, pp.244~250 (2010)
126. Huang MC, "Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan", Acta Psychiatr Scand, 120, pp.274~280 (2009)
127. Korean Society for Schizophrenia Research, "Guideline for cardiovascular and metabolic syndrome", Korean Society for Schizophrenia Research, ~ (2008)
128. De Hert M, "Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospective study of patients treated with second-generation antipsychotics", Schizophr Bull, 33, pp.560~ (2007)
129. Schorr SG, "Incidence of metabolic syndrome and its reversibility in a cohort of schizophrenic patients followed for one year", J Psychiatr Res, 43, pp.1106~1111 (2009)
130. Bobes J, "Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics : results of the CLAMORS Study", Schizophr Res, 90, pp.162~173 (2007)
131. Cohn T, "Characterizing coronary heart disease risk in chronic schizophrenia : high prevalence of the metabolic syndrome", Can J Psychiatry, 49, pp.753~760 (2004)
132. Meyer JM, "The Clinical Antipsychotic Trials Of Intervention Effectiveness(CATIE)schizophrenia trial : clinical comparison of subgroups with and without the metabolic syndrome", Schizophr Res, 80, pp.9~18 (2005)
133. Correll CU, "Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs", J Clin Psychiatry, 67, pp.575~583 (2006)
134. Correll CU, "Does antipsychotic polypharmacy increase the risk for metabolic syndrome", Schizophr Res, 89, pp.91~100 (2007)
135. Hägg S, "High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia", Int Clin Psychopharmacol, 21, pp.93~98 (2006)
136. Sicras-Mainar A, "Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice : a cross-sectional assessment of a primary health care database", Eur Psychiatry, 23, pp.100~108 (2008)
137. Saddichha S, "Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study", Schizophr Res, 101, pp.266~272 (2008)
138. Srisurapanont M, "Metabolic syndrome in Thai schizophrenic patients : a naturalistic one-year follow-up study", BMC Psychiatry, 23, pp.7~14 (2007)

관련 논문AI추천